This Article Order Full text via Infotrieve Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lyden, P. D. Articles by Lonzo, L. Search for Related Content PubMed PubMed Citation Articles by Lyden, P. D. Articles by Lonzo, L.

Stroke, Vol 25, 189-196, Copyright © 1994 by American Heart Association

ARTICLES

Combination therapy protects ischemic brain in rats. A glutamate antagonist plus a gamma-aminobutyric acid agonist

PD Lyden and L Lonzo
Department of Neurosciences, University of California at San Diego School of Medicine.

BACKGROUND AND PURPOSE--The excitotoxic effects of glutamate can be blocked almost completely with gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, in cell culture, tissue slices, and in some animal models. After stroke in rats, we showed previously that an agonist of GABA, muscimol, was as neuroprotective as MK-801, an antagonist of glutamate. To obtain further neuroprotection and to avoid the side effects associated with high doses of MK-801, we wanted to assess the efficacy of the two agents in combination. METHODS-- Treatment was administered 5 minutes after embolic cerebral ischemia in Sprague-Dawley rats. The subjects were rated using a neurological evaluation 48 hours later. Visual-spatial learning was measured 8 to 10 weeks after stroke, after which we measured the volume of each cerebral hemisphere and several large cerebral compartments. Treatment groups included saline (n = 27), MK-801 1.0 mg/kg (n = 23), muscimol 1.0 mg/kg (n = 17), and both agents together using a dose of 0.5 mg/kg each (n = 25). RESULTS--A probit analysis of the neurological ratings revealed a protective effect of muscimol used alone (MK-801 potency ratio, 2.0; P = NS; muscimol potency ratio, 4.0; P < .05) and a protective effect of the combination (potency ratio, 5.0; P < .05). Focal ischemia caused a moderate to severe delay in the acquisition of visual-spatial information, which was completely eliminated by the combination treatment but only partially ameliorated with MK-801 or muscimol alone. Ischemia reduced the cerebral hemisphere volume from 0.42 mm3 to 0.34 mm3 (P < .0001), the volume density of cortex from 22% to 17% of total cerebral volume (P < .01), and that of hippocampus from 4.3% to 3.0% (P < .05). Only the combination was neuroprotective, as measured by the ratio of the lesioned to the contralateral hemisphere volume (P = .013). The combination treatment and MK-801 protected the hemisphere volume, the cortex, and the hippocampus and reduced the size of visible infarction. CONCLUSIONS--Combination therapy, using a glutamate antagonist and a GABA-A agonist, appeared to protect the brain and ameliorate a defect in learning behavior after stroke. The combination may have been more effective than either agent used alone, although further study of higher doses is needed.

This article has been cited by other articles:

				K. Mukhida, I. Mendez, M. McLeod, N. Kobayashi, C. Haughn, B. Milne, B. Baghbaderani, A. Sen, L. A. Behie, and M. Hong Spinal GABAergic Transplants Attenuate Mechanical Allodynia in a Rat Model of Neuropathic Pain Stem Cells, November 1, 2007; 25(11): 2874 - 2885. [Abstract] [Full Text] [PDF]

				M. Fisher, A. Davalos, A. Rogalewski, A. Schneider, E. B. Ringelstein, and W.-R. Schabitz Toward a Multimodal Neuroprotective Treatment of Stroke Stroke, April 1, 2006; 37(4): 1129 - 1136. [Abstract] [Full Text] [PDF]

				K. Madden, W. Clark, and N. Lessov Failure of Ischemic Neuroprotection by Potentiators of Gamma-aminobutyric Acid Clin. Med. Res., April 1, 2003; 1(2): 119 - 124. [Abstract] [Full Text] [PDF]

				D. J. Gladstone, S. E. Black, and A. M. Hakim Toward Wisdom From Failure: Lessons From Neuroprotective Stroke Trials and New Therapeutic Directions Stroke, August 1, 2002; 33(8): 2123 - 2136. [Abstract] [Full Text] [PDF]

				Recommendations for Clinical Trial Evaluation of Acute Stroke Therapies Stroke, July 1, 2001; 32(7): 1598 - 1606. [Abstract] [Full Text] [PDF]

				P. Lyden, C. Shin, C. Jackson-Friedman, S. Hassid, A. Chong, and R. L. Macdonald Effect of Ganaxolone in a Rodent Model of Cerebral Hematoma Editorial Comment Stroke, January 1, 2000; 31(1): 169 - 175. [Abstract] [Full Text] [PDF]

				G. B Frisoni, M. Manfredi, C. Geroldi, G. Binetti, O. Zanetti, A. Bianchetti, and M. Trabucchi The prevalence of apoE-epsilon 4 in Alzheimer's disease is age dependent J. Neurol. Neurosurg. Psychiatry, July 1, 1998; 65(1): 103 - 106. [Abstract] [Full Text]

				A. G. Dyker and K. R. Lees Duration of Neuroprotective Treatment for Ischemic Stroke Stroke, February 1, 1998; 29(2): 535 - 542. [Abstract] [Full Text] [PDF]

				P. D. Lyden, C. Jackson-Friedman, L. Lonzo-Doktor, and J. P. Muizelaar Medical Therapy for Intracerebral Hematoma With the {gamma}-Aminobutyric Acid-A Agonist Muscimol Stroke, February 1, 1997; 28(2): 387 - 391. [Abstract] [Full Text]

				M. D. Ginsberg Review : Neuroprotection in Brain Ischemia: An Update (Part II Neuroscientist, May 1, 1995; 1(3): 164 - 175. [Abstract] [PDF]